Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure
In this medfyle
Heart failure is an important consideration in people with T2D.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About the Expert
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA, USA
Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has served on the ADA Board of Directors and several committees. He has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology. He has served on committees writing guidelines for both organizations. He has held a leadership role and served on various committees in several other organizations including the American Board of Internal Medicine. Dr. Fonseca has served on and been chairman of the clinical practice committee of the American Diabetes Association, the ADA Disaster Task Force, ADA strategic planning committee. He has played a significant role in developing guidelines for treating diabetes (ADA and AACE), managing chronic disease and clinical trials after a natural disaster and in drawing attention to the global epidemic of diabetes, particularly in Asia. The American Diabetes Association awarded him the ADA Banting Medal for Leadership and Service and the Southern Medical Association awarded him the Seale-Harris award. The ADA presents the Vivian Fonseca Award annually for research on Diabetes in Asia. He has received several teaching awards and was elected to the Alpha Omega Alpha Honor Medical Society and has been listed for several years among the Best Doctors in the USA and for several years rated by Expertscape among the top 10 experts in Diabetes worldwide. Dr. Fonseca is a fellow of the Royal College of Physicians (London).
He plays a significant role in Clinical Research as Assistant Dean at Tulane University, and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) Program. He is the Medical Director of the Tulane Clinical Trials Unit and Director of the Research Professional Development Core, which runs the Masters in Science in Clinical Research program.
He is Editor in Chief of the Journal of Diabetes and its Complications. He was Editor in chief of Diabetes Care, from 2007 to 2011, having formerly been associate editor. He was until 2006 Editor in Chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism, and is an ad hoc reviewer for several other journals, including New England Journal of Medicine, Lancet, JAMA, Diabetes, etc.
Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. He has a research program evaluating inflammation in diabetes, and using technology to improve diabetes care in underprivileged populations, especially the use of a new diabetes risk engine in clinical practice. He is the Louisiana PI of the All of Us Program, Southern Network and Co – PI of REACHnet a large network that conducts research utilizing electronic health records of over 2 million people across several states.
Dr Fonseca has a strong interest in facilitating clinical research and developing the next generation of translational researchers.
Dr. Fonseca has lectured in the United States and abroad. He has published nearly 500 papers and review articles. He is the editor of the text book “Clinical Diabetes: Translating Research into Practice” (El Sevier) and several monographs and book chapters.
Disclosures:
Research Support (to Tulane): Grants from Fractyl, Jaguar Gene Therapy
Honoraria for Consulting and Lectures: Takeda, Novo Nordisk, Sanofi- Aventis, Bayer Abbott, Astra- Zeneca, Intarcia, Asahi
Stock Options: - Mellitus Health, BRAVO4Health
Stock- Amgen
Acknowledgements
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Clinical Diabetes®, an official journal of the American Diabetes Association®, and is published in coordination with Sheridan. This MedFyle was created by GlobalPort (International) Limited with permission from the American Diabetes Association; neither Sheridan nor the American Diabetes Association takes any responsibility for its accuracy or for the use of any content therein by those reading or downloading such content.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Vivian Fonseca, MD, Tulane University Health Sciences Center, New Orleans, LA, USA.
Original article:
Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. Christie A. Schumacher, Elizabeth K. Van Dril, Kayce M. Shealy, Jennifer D. Goldman. Clinical Diabetes Aug 2020, cd200008; DOI: 10.2337/cd20-0008
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Diabetes Association.
References
1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34.
2. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879–84.
3. Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematicreview and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 2019;62:1550–60.
4. Dunlay SM, Givertz MM, Aguilar D, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140:e294–324.
5. Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes 2016;65:44–52.
6. Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010;120:1506–14.
7. Levelt E, Rodgers CT, Clarke WT, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 2016;37:3461–69.
8. Falcão-Pires I, Hamdani N, Borbély A, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosisthrough altered myocardial structure and cardiomyocyte stiffness. Circulation 2011;124:1151–9.
9. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63:582–92.
